2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,

Plaintiff,

v.

ROGER JINTEH ARRIGO CHEN, et al., Defendants.

Case No. 16-cv-07396-EMC

ORDER DENYING DEFENDANTS' MOTION TO DISMISS PLAINTIFF'S FIRST AMENDED COMPLAINT

Docket No. 53

I. **INTRODUCTION**

The Regents of the University of California ("the University") brought this suit alleging that a former research employee, Defendant Roger Jinteh Arrigo Chen, violated his contractual agreement by failing to assign his inventions to the University. See Docket No. 48 ("FAC") ¶ 1. After leaving the University, Chen started a company, Defendant Genia Technologies, Inc. ("Genia"), which sought to commercialize the technology the University claims Chen invented during his prior employment. Chen secured patents based on the disputed technology, and assigned those patents to Genia. The University filed the instant suit asserting a claim for Correction of Inventorship under 35 U.S.C. § 256, as well as seven state-law contract and tort claims relating to Chen's alleged breach of his agreement. Now pending before the Court is Defendants' motion to dismiss the University's First Amended Complaint. Docket No. 53. The Court **DENIES** the motion.

II. FACTUAL AND PROCEDURAL BACKGROUND

The following facts are drawn from the University's FAC. In October 2005, Chen enrolled in a Ph.D. program in Biochemistry at the University of California at Santa Cruz ("UCSC"). FAC

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

¶ 15. While at UCSC, Chen worked as a researcher in a biophysics laboratory run by Mark A. Akeson and David W. Deamer, scientists working in the field of DNA nanopore sequencing.¹ FAC ¶ 16. As a condition of his employment in the lab, Chen was required to sign the University's State Oath of Allegiance, Patent Policy, and Patent Acknowledgment. Id. The Patent Acknowledgment provides that (1) Chen has an "obligation to assign inventions and patents" that he conceived or developed during the time he was employed by the University or while using the University's research facilities, resources, or funds; (2) Chen has an "obligation to promptly report and fully disclose the conception and/or reduction to practice of potentially patentable inventions" to the University so that it could "determine [its] rights and equities therein"; (3) if the University determined that any such invention was patentable, Chen was required to execute any documents necessary to assign all patent rights to the University; and (4) the University would provide Chen with a percentage of any royalty payments obtained based on licensing Chen's inventions. FAC ¶ 17. Chen executed this agreement on September 15, 2005.

During his time at the UCSC lab, Chen, along with various co-inventors, developed a number of inventions "relating to a computer chip containing an array of individually addressable nanopores in membranes." FAC ¶ 21. These inventions were recorded in a series of Disclosures and Records of Invention, identifying Chen as either sole inventor or co-inventor. FAC ¶ 22.

Mark Akeson co-developed with Chen two concepts relevant to the inventions: First, "the concept of binding a large blocking molecule to a polynucleotide molecule so that an enzyme in solution . . . could not modify the polynucleotide"; and second, "the concept of providing an array of individually addressable nanopores formed in a membrane for characterizing and/or sequencing each of a plurality of polynucleotide molecules." FAC ¶ 27. David Deamer, a professor at UCSC working in the same lab, originally conceived the idea of "using nanopores for sequencing of polynucleotide molecules" and he co-developed, with Akeson, "the use of enzymes such as exonucleases and polymerases to control the movement of a polynucleotide molecule passing

Nanopore sequencing is a method of determining the precise order of nucleotides within a DNA molecule that makes use of very small holes (nanopores) whose diameter is on the order of one billionth of a meter. FAC ¶ 20.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

through a nanopore so that the polynucleotide molecule could be sequenced." FAC ¶ 30. Additionally, two other researchers, William B. Dunbar and Noah A. Wilson, made relevant contributions to the inventions, and are identified with Chen and others on other disclosures of inventions. FAC ¶ 28. In particular, "Wilson and Dunbar developed at least the use of voltage feedback control and a finite state machine to control the movement of polynucleotide molecules captured in nanopores and measure electrical signals across the nanopores, as well as its associated computerized processor and automation equipment." FAC ¶ 30.

Between 2007 and 2016, the University filed a series of related patent applications seeking protection for the inventions discussed above; each of the applications lists Chen as an inventor, along with one or more of the other researchers. FAC ¶ 32. Akeson, Deamer, Dunbar, and Wilson each assigned their rights in the patent applications to the University. FAC ¶ 33. The University filed the first three of these applications in 2007 while Chen was still employed at the University. FAC ¶ 39. Shortly after he left his employment in January 2008, the University filed two additional applications. FAC ¶ 40. Beginning in early 2009, the University asked Chen to execute declarations pertaining to these patent applications, but between 2009 and 2010 "Chen either failed to respond or was evasive when the University" asked him to do so. FAC ¶ 42. During this period, Chen was launching Genia, which was officially founded in March 2009. FAC ¶ 44.

On October 17, 2013, the University filed an additional patent application, and subsequently asked Chen to execute an Inventor's Oath or Declaration as to that application, and also asked him to execute assignment as to the six previously filed applications. FAC ¶ 46. After asking for additional information, on March 5, 2014, Chen sent a letter stating "I do not believe I contributed to material in the claims in this application. Thus, I do not believe I am an inventor on this application" and advising the University to review his written materials from his time at UCSC. FAC ¶ 48. The University was unable to locate any such materials, and allege that "Chen failed to return those materials to the University, even though he was required to do so per the terms of his employment and the University's policy." FAC ¶ 49. The University states that it had no reason to look for Chen's materials prior to receiving his 2014 letter.

Genia's business model is based on nanopore sequencing. Genia has secured five patents related to this technology which list Chen as one of two co-inventors, along with Randy Davis, another Genia employee who never worked at UCSC. FAC ¶ 58. According to the University, "[t]he subject matter of the Genia Patents, and the claims and inventions disclosed therein, were conceived and developed by Chen (and his University co-inventors) during his employment with the University." FAC ¶ 57. The first Genia Patent was filed on February 8, 2010. Its pre-grant publication date was August 8, 2011, and it was issued on December 4, 2012. *Id.* Genia filed additional patent applications in the following years, and its additional patents were issued on June 11, 2013, May 26, 2015, and June 28, 2016. *Id.* Most recently, Genia filed a patent application on March 24, 2016, which was published on November 24, 2016, and has not yet been issued. *Id.*

The University learned of the Genia Patents sometime shortly before June 10, 2014, when it filed an additional patent application containing claims copied from Genia's '854 patent, which had been issued on June 11, 2013. FAC ¶ 50. The University again asked Chen to sign inventors' declarations and assignments regarding this application, and requested that he provide a copy of his written materials. *Id.* Chen responded, through counsel, asking for additional information regarding the University's claims. Over the next "several months," Chen continued to engage in "evasive tactics," including requesting additional information and "advancing various excuses as to why he had not executed the requested documents." FAC ¶ 53. To date, Chen has not executed any declarations or assignments relating to the University's patent applications. FAC ¶ 55.

In June 2014, Roche, one of the largest healthcare companies in the world, agreed to acquire Genia for \$125 million, plus another \$225 million contingent on achieving certain milestones. FAC ¶ 62. The University states that "[u]pon information and belief, a significant portion of the Acquisition Payment is attributable to the value of the Genia Patents, which are one of Genia's most valuable assets." FAC ¶ 63.

Although Genia's first patent application was published on August 11, 2011 and issued as the Genia '914 patent on December 4, 2012, the University alleges that it did not know of the patent until sometime in 2014. The University was not aware that Chen had co-founded Genia in March 2009 and had begun pursuing competing patent applications in 2010. Thus, the University

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

alleges that it "had no reason to suspect that Chen was improperly using the UCSC Inventions, so as to trigger a duty to investigate whether any patents or published patent applications naming Chen as an inventor incorporated the UCSC Inventions." FAC ¶ 68. The University alleges that to the extent Chen breached his contractual obligations regarding to the University's 2007-2008 applications, those breaches were insufficient to put the University on notice that he would breach his agreement with respect to the later-filed applications. FAC ¶ 66. The University further alleges that Chen engaged in "evasive conduct" and made "continued representations suggesting he might comply with the University's requests to fulfill his obligations under the Patent Agreement." Id. This "misconduct induced the University into forbearing suit," FAC ¶ 72, and equitably estops Chen and Genia from asserting a statute of limitations defense. FAC ¶ 74.

Based on the above allegations, the University brought the instant action, asserting claims for (1) Correction of Inventorship Under 35 U.S.C. § 256; (2) Declaration of Patent Ownership; (3) Breach of Contract; (4) Breach of the Implied Covenant of Good Faith and Fair Dealing; (5) Conversion; (6) Inducing Breach of Contract; (7) Intentional Interference with Contractual Relations; and (8) Constructive Trust. Defendants move to dismiss on the following grounds: (1) the University's claim for Correction of Inventorship fails to state a claim; (2) the University's state law claims are time-barred; (3) the University's state law claims are preempted by federal patent law; and (4) the University's contract and derivative tort claims fail because the patent agreement between Chen and the University unambiguously imposes no post-employment duty on Chen.

III. **DISCUSSION**

Standard of Review Α.

Under Rule 12(b)(6), a party may move to dismiss based on the failure to state a claim upon which relief may be granted. A motion to dismiss based on Rule 12(b)(6) challenges the legal sufficiency of the claims alleged. See Parks Sch. of Bus. v. Symington, 51 F.3d 1480, 1484 (9th Cir. 1995). In considering such a motion, a court must take all allegations of material fact as true and construe them in the light most favorable to the nonmoving party, although "conclusory allegations of law and unwarranted inferences are insufficient to avoid a Rule 12(b)(6) dismissal." For the Northern District of California

Cousins v. Lockyer, 568 F.3d 1063, 1067 (9th Cir. 2009). While "a complaint need not contain detailed factual allegations . . . it must plead "enough facts to state a claim to relief that is plausible on its face." Id. "A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged." Ashcroft v. Iqbal, 556 U.S. 662 (2009); see also Bell Atl. Corp. v. Twombly, 550 U.S. at 556. "The plausibility standard is not akin to a 'probability requirement,' but it asks for more than sheer possibility that a defendant acted unlawfully." *Iqbal*, 556 U.S. at 678.

В. Count One

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

The University's first claim for relief is for correction of inventorship under 35 U.S.C. § 256, which permits a court to order the correction of a patent "[w]henever through error a person is named in an issued patent as the inventor, or though error an inventor is not named in an issued patent." Specifically, the University asks that the Court correct the four issued Genia patents—the '914, '854, '420, and '437 patents—by removing Randy Davis and adding Mark Akeson, David Deamer, William Dunbar, and Noah Wilson. FAC ¶ 87. Defendants contend that the University has failed to set forth sufficient facts to support this claim under Iqbal and Twombly. In particular, Defendants argue that the University makes general claims that "several UCSC employees 'contributed to the conception' of various concepts regarding nanopore technology . . . and that the UCSC employees and Mr. Chen 'jointly conceived' of certain systems allegedly 'claimed' in some of the Genia Patents." Motion at 23. According to Defendants, the University did not make sufficient "assertions regarding what the Genia Patent claims state, or what part of those patents claims is novel (i.e., inventive rather than simply part of the technological background)." Id.

The Court disagrees. As the University correctly points out, Defendants' selective reading of the complaint entirely elides the fact that, over the course of several pages, the University's FAC goes into considerable detail regarding specific contributions made by each of the University scientists to particular methods and ideas underlying the patents, see FAC ¶¶ 80-82, and further explains how these conceptions relate to specific systems claimed in each of the Genia Patents, see FAC ¶¶ 83-85. Indeed, the FAC "recite[s] specific elements from the Genia Patent claims that each inventor conceived." Docket No. 58 ("Opp.") at 10.

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

In reply, the Defendants do not effectively respond to these points; instead, they seek to distinguish a case relied upon by the University on the ground that in that case, there were specific allegations of "corroborating evidence of conception" such as when and how information was shared between the inventors. Docket No. 59 ("Reply") at 13 (quoting Quintel Tech. Ltd. v. Huawei Techs. USA, Inc., No. 415CV00307GHDCMC, 2016 WL 5423178, at *18 (E.D. Tex. Sept. 27, 2016)). But the University includes specific allegations about how each of the researchers collaborated during their time working at the UCSC lab. These allegations are sufficient to state a plausible claim under *Iqbal* and *Twombly*, and the Court therefore **DENIES** Defendants' motion with respect to Count One.

C. Counts Two through Eight

1. Statute of Limitations

With respect to the University's state law claims, Counts Two through Eight, Defendants first argue that each is time barred as a matter of law. As the parties apparently agree, the statutes of limitations are two years for Plaintiff's claims against Genia for tortious interference with contract and inducing breach of contract (Counts Six and Seven), three years for Plaintiff's conversion claim (Count Five), and four years for Plaintiff's patent ownership and breach of contract claims (Counts Two through Four).² Motion at 7 (citing authorities for each of the relevant limitations periods). This action was filed on December 29, 2016, which means that the critical date for the longest limitations period is December 29, 2012. Defendants argue that all of the University's claims accrued before that date, for several reasons.

Constructive Notice a.

Defendants' primary argument is twofold: First, the publication, on August 11, 2011, and issuance, on December 4, 2012, of the first Genia Patent, put the University on constructive notice of its claims. Second, because the subsequent Genia Patents are continuation patents related to the first, the first Genia Patent triggered the statute of limitations for *all* of the University's claims,

² Defendants assert that "Plaintiff's constructive trust claim (Count VIII) is a remedy, not a standalone claim, subject to the statutes of limitations for the other claims, depending on the underlying substantive right." Motion at 8 (citing *Davies v. Krasna*, 14 Cal. 3d 502, 515-16 (Cal. 1975)). The University does not dispute this point.

even as to the subsequent patents.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

With respect to constructive notice, the Supreme Court has long held that "issuance of a patent and recordation in the Patent Office constitute notice to the world of its existence." Wine Ry. Appliance Co. v. Enter. Ry. Equip. Co., 297 U.S. 387, 393 (1936). Following Wine Railway, the Ninth Circuit and this Court have held that "publication of patents (and now patent applications) must be deemed, as a matter of law, to place those practicing in the same field and prosecuting their own patent applications in the same field on full notice of all of the contents of the publication." Wang v. Palo Alto Networks, Inc., No. C 12-05579 WHA, 2014 WL 1410346, at *6 (N.D. Cal. Apr. 11, 2014); see also Gen. Bedding Corp. v. Echevarria, 947 F.2d 1395, 1398 (9th Cir. 1991) (holding that where the publication of a patent would alert a reasonable person to the "need to inquire further," the statute of limitations on claims arising from the patent would begin to run with publication). It is undisputed that with respect to the patents at issue, the University and Defendants are "practicing in the same field," i.e. the field of nanopore technology. Accordingly, as Defendants argue, the issuance of the first Genia Patent, on December 4, 2012, "gave Plaintiff notice that (1) Mr. Chen and Genia sought patent protection on inventions directed to nanopore technology; (2) Mr. Chen had not assigned the application or patent to Plaintiff; and (3) Mr. Chen claimed the inventions set forth therein for himself and Genia." Motion at 12. This sufficed to put the University on notice of all claims arising out of this patent, and accordingly Chen's failure to assign his rights to the University.

The University states that some courts have "flatly rejected" the argument that the issuance of a patent constitutes constructive notice of its existence as a matter of law. Opp. at 22. But the University only cites two district court cases that have reached this conclusion, and only one of them, Applera Corp.-Applied Biosystems Grp. v. Illumina, Inc., No. C-07-02845-WHA, 2008 WL 927963, at *1–2 (N.D. Cal. Apr. 4, 2008), is from a court within this Circuit. As Defendants rightly point out, the author of the Applera order, Judge Alsup, subsequently explicitly repudiated it and held to the contrary that "publication of patents (and now patent applications) must be deemed, as a matter of law, to place those practicing in the same field and prosecuting their own patent applications in the same field on full notice of all of the contents of the publication." Wang,

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

2014 WL 1410346, at *6. The Supreme Court's decision in *Wine Railway*, and the Ninth Circuit's decision in General Bedding are binding on this Court, and the Court sees no basis for departing from them.

That is not the end of the matter, however, as the University contends that questions of fact remain that preclude the application of constructive notice in this case. First, noting its allegation in the FAC that it "had no knowledge of facts giving rise to its claims until it learned of the Genia Patents in 2014 and had no reason to suspect their existence prior that that time," Opp. at 23 (citing FAC ¶ 68), the University argues that its notice constitutes a question of fact that cannot be resolved on a Rule 12 motion to dismiss. But this conclusory allegation cannot defeat the University's constructive notice of the first Genia patent, for the reasons explained above. The University also contends that "Chen actively misled the University into believing that he would fulfill his obligations under the Patent Agreement," and that this misconduct prevented the University from discovering its claims earlier. This cannot be correct. The alleged misconduct the University cites were communications between the parties in 2014-2016, after the University became aware of the Genia Patents, see Opp. at 23-24 (citing FAC ¶¶ 45-54, 68, 71-74), and after it had constructive notice of the first Genia patent.

Second, the University argues that Chen's misconduct "induced the University into forbearing suit," FAC ¶ 72, and that accordingly Chen should be equitably estopped from asserting a statute of limitations defense. The University contends that at the very least, "the reasonableness of the University's reliance on Defendants' wrongful conduct presents a fact issue that cannot be resolved on a motion to dismiss." Opp. at 25. This argument fails for two reasons. First, as Defendants note, this Court has explained that equitable estoppel "does not come into play, whatever the lengths to which a defendant has gone to conceal the wrongs, if a plaintiff is on notice of a potential claim." Raifman v. Wells Fargo Advisors, LLC, No. C 11-02885 SBA, 2014 WL 12013436, at *12 (N.D. Cal. Mar. 31, 2014), aff'd sub nom. Raifman v. Wachovia Sec., LLC, 649 F. App'x 611 (9th Cir. 2016) (emphasis in original). By the time of Chen alleged misconduct, the University was on both actual and constructive notice of its potential claims. It cannot be heard to complain, therefore, that any actions on Chen's part prevented it from filing suit. Second,

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

the University's allegations regarding Chen's "misconduct" are conclusory. What the University characterizes as "evasive tactics," FAC ¶ 53, appear to be nothing more than Chen's requests for additional information about the University's claims, and his refusal, through counsel, to sign documents related to the University's patent applications between 2014 and 2016. See generally FAC ¶¶ 45-55.

Defendants next argue that the issuance of the first Genia Patent triggered the limitations period for all of the University's claims, even as to the later-issued patents, because the subsequent patents were "continuation patents" based on the first patent. Motion at 13. A continuation patent "is a second application that contains the same disclosure as the original application," and "may not contain anything that would have been considered 'new matter' if inserted in the original application." 4 A Donald S. Chisum, Chisum on Patents § 13.03[2]; see also 4 Pat. Law Fundamentals § 15:8 (2d ed.) ("A continuation carries forward the disclosure from a previous application but adds nothing new."); V-Formation, Inc. v. Benetton Grp. SpA, 401 F.3d 1307, 1308 (Fed. Cir. 2005) (explaining that the specification and drawings of parent patents and continuation patents are the same). Thus, in this case, "all of the Genia Patents and applications are directed to inventions that were originally disclosed in the initial Genia Patent application." Motion at 13. For that reason, Defendants argue, the University "had notice of all causes of action arising out of Mr. Chen's alleged failure to assign and/or disclose these inventions, including those that were described in the original Genia Patent yet claimed in later-issued Genia Patents." Motion at 14.

In support of this position, Defendants principally rely on the Federal Circuit's holding in Board of Trustees of Leland Stanford Junior University v. Roche Molecular Systems, Inc., 583 F.3d 832 (Fed. Cir. 2009). In Stanford, the court found that the statute of limitations barred Roche's claims where evidence showed that it had notice of one patent that had already issued, and also knew that "continuations based on the same application 'family' remain pending" and that Stanford claimed ownership "patents that may issue" based on those applications. Id. As here, Roche argued that its causes of action as to later filed patents could not accrue until those patents actually issued, but the Court held that Roche was on notice regarding possible "additional

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

patents as to the same subject matter," even though the applications at issue had not yet been filed when Roche received such notice. According to Defendants, Stanford thus stands for the proposition that "the statute of limitations starts once the plaintiff is on notice that the defendant asserts ownership over the inventions and is seeking patent protection—it does not matter that some of those patents are applied for and issued after the critical date." Motion at 14.

Stanford, however, is distinguishable from this case. In Stanford, the plaintiff had actual notice of the issued patent, as well as of defendants' claim of ownership over related patents that "may issue." The Court's holding was in part dependent on those specific facts. By contrast, in this case the University alleges that it had no actual notice of the first Genia Patent, but even assuming it had constructive notice of that patent, it was not aware that Genia planned to seek additional continuation patents as was the case in *Stanford*. Defendants argue that the University's constructive notice of the first Genia patent should have put it on notice of the need to inquire further into any additional patents, and they contend that any reasonable investigation would have revealed that by the date of the first patent, Defendants were already seeking a continuation patent, which had been filed on September 15, 2012.³ Reply at 6. There may well be merit to this argument, but as the Ninth Circuit has explained, the determination of what a party "discovered or could have discovered with the exercise of reasonable diligence" is ordinarily a quintessential question of fact that cannot be resolved at the motion to dismiss stage at least where, as here, the University may not have had actual notice of existing and future continuation patents. General Bedding, 947 F.2d at 1396 n.2; see also Beneficial Standard Life Ins. Co. v. Madariaga, 851 F.2d 271, 275 (9th Cir. 1988) ("Ordinarily we leave the question of whether a plaintiff knew or should have become aware of a fraud to the jury."). Even assuming the University's constructive knowledge of the first Genia patent, therefore, the determination of what the University should have discovered through "reasonable investigation" sufficiently appears to be a question of fact so as to preclude a finding as a matter of law at this juncture. For that reason, the Court cannot conclude that the University had constructive notice of its claims with respect to the later-filed

³ Information about continuation patents is available to the public upon inquiry into the original patent. *See* Manual of Patent Examining Procedure § 102; 37 C.F.R. § 1.14(a)(2)(iv).

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

patents for purposes of the motion to dismiss.

b. Duty to Investigate

In addition to the above argument, the Defendants contend that the University's claims are time-barred for an additional reason. As noted above, the University alleges that in 2007 and 2008, while Chen was still at UCSC and shortly after he left, the University filed three patent applications related to nanopore technology. FAC ¶ 39-40. Beginning in early 2009, the University asked Chen to execute declarations pertaining to these patent applications, but between 2009 and 2010 "Chen either failed to respond or was evasive when the University" asked him to do so. FAC ¶ 42. According to Defendants, "UCSC's allegation that Mr. Chen repeatedly failed (and refused) to sign the applications . . . is therefore fatal to any assertion that UCSC was unaware of Chen's alleged breach," and "[a]t the very least, these facts triggered Plaintiff's duty to investigate possible claims." Motion at 10-11. Had the University timely investigated Chen's refusal to sign these documents, it would have discovered immediately that Chen had started Genia, rather than not discovering that fact until 2014, as the University alleges.

As with constructive notice question, however, the question of what exactly the University knew or suspected and what knowledge it should be charged with must be considered at this stage to be a fact-intensive inquiry. Moreover, as the University points out, its present claims are not premised on any breach during 2007-2009, but rather on Chen's later failure to assign the Genia Patents.

In sum, the Court cannot conclude at this stage that the University's claims are time-barred as a matter of law in the context of the Rule 12(b)(6) motion. Defendants' motion is therefore **DENIED** as to the timeliness issue.

2. Federal Preemption

Defendants further argue that the University's state claims are preempted by federal patent law. Motion at 18-22. Because the rules for determining inventorship are established in federal law, the Federal Circuit and other federal courts have frequently explained that ""the field of federal patent law preempts any state law that purports to define rights based on inventorship." HIF Bio, Inc. v. Yung Shin Pharm. Indus. Co., 600 F.3d 1347, 1353 (Fed. Cir. 2010)

patent law." Speedfit LLC v. Woodway USA, Inc., No. 13-CV-1276 (KAM), 2016 WL 7471307, at *7 (E.D.N.Y. Dec. 28, 2016). By that same token, "claims that can be established without reference to patent inventorship or ownership are generally not preempted by federal patent law." Gerawan Farming, Inc. v. Rehrig Pac. Co., No. 1:11-CV-01273 LJO, 2012 WL 691758, at *7 (E.D. Cal. Mar. 2, 2012). Thus, courts have held preempted, e.g., state law conversion claims based on allegations that defendants misappropriated intellectual property rights "by securing patents from the PTO for the same subject matter as Plaintiff's patents," Lyden v. Nike Inc., No. 3:13-CV-00662-HZ, 2014 WL 2563401, at *2-3 (D. Or. June 6, 2014), or by "improperly omit[ing] [the plaintiff] as an inventor on . . . [a] patent application," Brown v. Brown, No. CV 13-03318 SI, 2013 WL 5947032, at *7 (N.D. Cal. Nov. 5, 2013). In each of these cases, the Court was unable to resolve the state law claims without making a determination regarding the plaintiff's claim to inventorship.

(quoting Univ. of Colo. Found. v. Am. Cyanamid Co., 196 F.3d 1366, 1372 (Fed. Cir. 1999)).

Thus, a state law claim that "turns on a determination of inventorship is preempted by federal

Defendants claim that each of the University's state law claims likewise requires a determination of inventorship insofar as they require a determination of whether Chen and the other University researchers conceived of the inventions in question while working at UCSC. But as the University rightly points out, its claims are not dependent on a determination of ownership. This is true because, according to the University's allegations, "even if inventorship on the face of the Genia Patents is correct, the University is entitled to joint ownership of those patents based at least on Chen's obligations to assign the inventions claimed in the Genia Patents to the University, as well as Chen's conversion of University property." Opp. at 6. The key question is not who invented the inventions described in the Genia Patents – it is undisputed that Chen is at least one of the proper inventors – but rather when they were invented: while Chen was still at UCSC or after he had left to found Genia. Whether Chen breached his contractual obligations to the University, and whether he wrongfully converted property that belongs to the University, depend primarily on "factual questions of when certain of Chen's actions occurred rather than a more complete determination of inventorship." Opp. at 6.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Significantly, none of the preemption cases that Defendants cite involved a similar situation, where the identity of the inventor was undisputed and the claim turned primarily on the timing of the invention as such timing affects contractual rights. Similarly, as the University notes, Defendants cite no cases in which state law claims for breach of contract or contract-related torts were held to be preempted. The Federal Circuit has emphasized that courts "apply state law to contractual disputes and interpretations of the parties' patent assignment agreements." Intellectual Ventures I LLC v. Erie Indem. Co., 850 F.3d 1315, 1320 (Fed. Cir. 2017). The Court therefore agrees with the University that the state claims in this case are not preempted. Defendants' motion is **DENIED** as to the preemption issue.

3. The Scope of the Patent Agreement

Lastly, Defendants argue that the University's claims against Chen for breach of contract and breach of the implied covenant of good faith and fair dealing (Counts Three and Four), as well as the derivative tort claims against Genia for inducing breach and intentional interference with contractual relations (Counts Six and Seven) "fail as a matter of law because the Patent Agreement unambiguously provides that Mr. Chen was not bound after leaving UCSC, and each of Mr. Chen's alleged breaches occurred after Mr. Chen left UCSC." Motion at 23. The basis for this claim is one sentence in the Patent Agreement entered into between Chen and the University, which provides that "I acknowledge that I am bound during any periods of employment by University or for any period during which I conceive or develop any invention during the course of my utilization of any University research facilities, or any gift, grant, or contract research funds received through the University." FAC ¶ 16. Defendants argue that this language "unambiguously provides that Mr. Chen's duties end with his employment or use of University facilities or funds," and that as a result, one Chen had left UCSC he was under no continuing obligation to assign inventions and patents, even if he had conceived them during his time there. Motion at 24.

As the University explains, however, the standard industry practice for such agreements requires the disclosure of all inventions developed during employment. See, e.g., STMicroelectronics, Inc. v. Harari, No. C 05-4691 JF, 2006 WL 2032580, at *2 (N.D. Cal. July

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

18, 2006) ("Harari was required to disclose all inventions, period, as long as the temporal limitation in the Inventions Agreement was met (i.e., as long as the invention was conceived during Harari's term of employment.)"). Indeed, the University argues Defendants' interpretation would lead to an absurd result. Under Defendants' reading, any employee who conceived an invention during his employment could immediately quit, and claim it for himself, without any continuing obligation to assign rights to his employer. This would plainly have the effect of rendering any similar Patent Agreement utterly powerless, making it extremely unlikely that this is the interpretation of the Agreement that the parties understood themselves to be entering into.

Moreover, the entire text of the Agreement undermines Defendants' proffered construction of the Agreement. The sentence upon which Defendants rely in asserting the Agreement binds the employee only with respect to the activity of inventing, and not with respect to the obligation to assign rights, is read out of context. The Agreement elsewhere expressly provides that, when the University makes a determination that an invention conceived during employment is patentable, the employee agrees "to execute any documents and do all things necessary . . . to assign to University all rights, title, and interest therein and to assist University in securing patent or analogous protection thereon." FAC ¶ 16. This provision does not indicate any time limit on this obligation. Defendants' interpretation would effectively read this central provision out of the Agreement. See Cal. Civ. Code § 1641 ("The whole of a contract is to be taken together, so as to give effect to every part, if reasonably practicable, each clause helping to interpret the other."); Palmer v. Truck Ins. Exch., 21 Cal. 4th 1109, 1115 (1999).

The Court therefore holds that the Agreement is unambiguous as a matter of law. See Wolf v. Superior Court, 114 Cal. App. 4th 1343, 1350 (2004). Chen's obligation to assign does not end with his employment. The Court **DENIES** Defendants' motion to dismiss on this ground.

/// ///

///

27 ///

28 ///

United States District Court For the Northern District of California

IV. <u>CONCLUSION</u>

For the foregoing reasons, the Court **DENIES** Defendants' motion to dismiss the University's First Amended Complaint.

This order disposes of Docket No. 53.

IT IS SO ORDERED.

Dated: July 26, 2017

EDWARD M. CHEN United States District Judge